Evidence map›Paper›PMID 30619657›Full record

ArticleTranslational vision science & technology2018

Quantitative Analysis of Changes to Meibomian Gland Morphology Due to S-1 Chemotherapy.

Kazuyoshi Ohtomo, Reiko Arita, Rika Shirakawa, Tomohiko Usui, Hiroharu Yamashita, Yasuyuki Seto, Satoru Yamagami, TS-1 Multicenter Study Group

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational vision science & technology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Kazuyoshi OhtomoDepartment of Ophthalmology, Japan Community Healthcare Organization, Tokyo Shinjuku Medical Center, Tokyo, Japan.
Reiko AritaDepartment of Ophthalmology, University of Tokyo Hospital, Tokyo, Japan.
Rika ShirakawaDepartment of Ophthalmology, University of Tokyo Hospital, Tokyo, Japan.
Tomohiko UsuiDepartment of Ophthalmology, University of Tokyo Hospital, Tokyo, Japan.
Hiroharu YamashitaDepartment of Gastrointestinal Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Yasuyuki SetoDepartment of Gastrointestinal Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Satoru YamagamiDepartment of Ophthalmology, University of Tokyo Hospital, Tokyo, Japan.
TS-1 Multicenter Study Group
University of Tokyo Hospital · JPThe University of Tokyo · JPItochu (Japan) · JPJapan Community Healthcare Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this prospective, noncomparative, observational case series was to evaluate changes to meibomian gland morphology in patients undergoing S-1 chemotherapy with the use of noninvasive meibography and analytical software.

methodsPatients aged ≥20 years and undergoing S-1 chemotherapy were included. Ophthalmologic examinations were performed before S-1 administration (Pre) and at 1, 3, and 6 months afterward (1M, 3M, and 6M, respectively). Meibography images were analyzed using analytical software. The ratio of the total meibomian gland area relative to the whole measurement area (meibomian gland area ratio [MGAR]) and the rate of change to the MGAR (MGAR at Pre, 1M, 3M, or 6M)/(MGAR at Pre) × 100 were calculated.

resultsIn total, 28 eyelids of seven men (mean age, 68.9 ± 6.3 years) were studied. The mean MGAR of the upper and lower eyelids significantly decreased at 3M (

conclusionsThe meibomian gland area decreased after S-1 administration with significant correlations between the rate of change to the MGAR and the mean cumulative dose of S-1. TRANSLATIONAL RELEVANCE: Systemic S-1 administration decreased the MGAR in a dose-dependent manner; thus, clinicians should pay more attention to morphologic changes to the meibomian glands during early treatment with S-1.

Indexed as

meibographymeibomian glandmeibomian gland area ratioS-1tegafur

Identifiers

PMID30619657
PMCPMC6314225
OpenAlexW2908154868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.